US 12,280,058 B2
Gasotransmitter metabolites and Alzheimer's disease
Christopher Kevil, Shreveport, LA (US); Elizabeth Disbrow, Shreveport, LA (US); Jonathan Steven Alexander, Shreveport, LA (US); and Karen Y. Stokes, Shreveport, LA (US)
Assigned to BOARD OF SUPERVISORS OF LOUISIANA STATE UNIVERSITY AND AGRICULTURAL AND MECHANICAL COLLEGE, Baton Rouge, LA (US)
Filed by Board of Supervisors of Louisiana State University and Agricultural and Mechanical College, Baton Rouge, LA (US)
Filed on Mar. 12, 2021, as Appl. No. 17/200,746.
Claims priority of provisional application 62/988,522, filed on Mar. 12, 2020.
Prior Publication US 2021/0285938 A1, Sep. 16, 2021
Int. Cl. A61K 31/195 (2006.01); A61K 31/198 (2006.01); A61K 31/53 (2006.01); G01N 33/84 (2006.01)
CPC A61K 31/53 (2013.01) [A61K 31/195 (2013.01); A61K 31/198 (2013.01); G01N 33/84 (2013.01); G01N 2800/2821 (2013.01)] 3 Claims
OG exemplary drawing
 
1. A method of diagnosing and treating Alzheimer's disease and related dementias (ADRD) comprising:
obtaining a plasma sample from the patient;
determining a level of a biochemical sulfide in the plasma sample from the patient, the biochemical sulfide being one of acid-labile sulfide, bound sulfide, and total sulfide;
diagnosing the patient with ADRD when biochemical sulfide is above a cutoff; and administering an effective amount of a sulfide reducer to the diagnosed patient, wherein:
the sulfide reducer is a CSE inhibitor and includes one of L-propylarginine, L-aminoethoxyvinylglycine, I157172 (2-[(4-(2,5-dimethoxyanilino)-6-(3-nitroanilino)-1,3,5-triazin-2-yl) sulfanyl]-6-ethoxy-1,3-benzothiazole); or
the sulfide reducer is a CBS inhibitor and includes one of hydroxylamine, aminooxyacetic acid, trifluoroalanine, L-aminoethoxyvinylglycine, and both L-aminoethoxyvinylglycine and pyridoxamine; or
the sulfide reducer is an MST inhibitor and includes XMU-MP-1 (4-((5,10-dimethyl-6-oxo-6,10-dihydro-5H-pyrimido[5,4-b]thieno[3,2-e][1,4]diazepin-2-yl)amino)benzenesulfonamide).